Bayhill Therapeutics

company

About

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics.

  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
$35.40M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 2000
Number Of Employee
51 - 100
Operating Status
Active

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$51.20M
Bayhill Therapeutics has raised a total of $51.20M in funding over 2 rounds. Their latest funding was raised on Apr 11, 2006 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 11, 2006 Series Unknown $15.80M 2 Detail
May 4, 2005 Series B $35.40M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Bayhill Therapeutics is funded by 2 investors. Prudence Venture Investment Corporation and Boston Life Science Venture are the most recent investors.
Investor Name Lead Investor Funding Round
Prudence Venture Investment Corporation Series Unknown
Boston Life Science Venture Series Unknown